Therapy Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Therapy Name Tislelizumab
Synonyms
Therapy Description

Tislelizumab (BGB-A317) is a human monoclonal antibody that targets PD-1 (PDCD1), thereby blocking the binding of PD-L1 (CD274) and potentially resulting in activation of a T-cell immune response against tumor cells (PMID: 32769013, PMID: 32561638, PMID: 32540858).

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Tislelizumab BGB-A317 Immune Checkpoint Inhibitor 146 PD-L1/PD-1 antibody 112 Tislelizumab (BGB-A317) is a human monoclonal antibody that targets PD-1 (PDCD1), thereby blocking the binding of PD-L1 (CD274) and potentially resulting in activation of a T-cell immune response against tumor cells (PMID: 32769013, PMID: 32561638, PMID: 32540858).

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT05502250 Phase II Cisplatin + Gemcitabine + Tislelizumab Tislelizumab Tislelizumab, Gemcitabine and Cisplatin for R/R Hodgkin Lymphoma Followed by Tislelizumab Consolidation in Patients in Metabolic Complete Remission (HOVON164HL) Recruiting BEL 2
NCT05014815 Phase II BGBA1217 + Tislelizumab Tislelizumab Ociperlimab With Tislelizumab and Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer Active, not recruiting USA | FRA | ESP | AUT | AUS 2
NCT04837859 Phase II Tislelizumab Dacarbazine + Doxorubicin + Tislelizumab + Vinblastine Phase II Trial of Individualized Immunotherapy in Early-Stage Unfavorable Classical Hodgkin Lymphoma (INDIE) Not yet recruiting DEU 0
NCT03430843 Phase III Docetaxel Paclitaxel Tislelizumab Irinotecan A Study of BGB-A317 Versus Chemotherapy as Second Line Treatment in Patients With Advanced Esophageal Squamous Cell Carcinoma Completed USA | ITA | GBR | FRA | ESP | DEU | BEL 4
NCT04732494 Phase II BGBA1217 + Tislelizumab Tislelizumab AdvanTIG-203: Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma Active, not recruiting FRA | ESP 4
NCT04866017 Phase III Durvalumab BGBA1217 + Tislelizumab Tislelizumab A Study to Compare Ociperlimab Plus Tislelizumab Versus Durvalumab Following Concurrent Chemoradiotherapy (cCRT) in Patients With Stage III Unresectable Non-Small Cell Lung Cancer Active, not recruiting USA | AUS 0
NCT04746924 Phase III Tislelizumab BGBA1217 + Tislelizumab Pembrolizumab A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer Recruiting USA | ITA | FRA | ESP | DEU 7
NCT05977673 Phase II Tislelizumab Efficacy and Safety of Frontline Tislelizumab in Patients With de Novo Hodgkin Lymphoma Unsuitable for Standard Frontline Chemotherapy: a Phase II, Open-label Study (FIL_Tisle-HL) Not yet recruiting ITA 0
NCT04318080 Phase II Tislelizumab Tislelizumab in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma Active, not recruiting USA | FRA | BEL | AUS 1
NCT05245760 Phase II Tislelizumab ChemoRadiation And Tislelizumab for Esophageal/EGJ Cancer (CRATER) Withdrawn USA 0
NCT05622071 Phase II Tislelizumab Testing Immunotherapy for Patients With Liver Cancer and Moderately Altered Liver Functions (HESTIA) Recruiting FRA 0
NCT05635708 Phase II Nab-paclitaxel Cisplatin BGB-A445 + Tislelizumab Paclitaxel Tislelizumab Carboplatin Pemetrexed Disodium LBL-007 + Tislelizumab A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer Recruiting USA | ESP | AUS 7
NCT03412773 Phase III Tislelizumab Sorafenib Phase 3 Study of BGB-A317 Versus Sorafenib in Patients With Unresectable HCC Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU 5
NCT03419897 Phase II Tislelizumab Study of BGB-A317 in Patients With Previously Treated Unresectable HCC Completed ITA | GBR | FRA | ESP | DEU 3
NCT02407990 Phase I Tislelizumab Study of the Safety, Pharmacokinetics and Antitumor Activities of BGB-A317 in Subjects With Advanced Tumors Completed USA | AUS 3
NCT04164199 Phase III Pamiparib + Tislelizumab Pemetrexed Disodium + Tislelizumab Tislelizumab Capecitabine + Tislelizumab Pamiparib Study of Tislelizumab and/or Pamiparib Containing Treatments in Participants With Advanced Malignancies Enrolling by invitation 4
NCT05909904 Phase II LBL-007 + Tislelizumab Tislelizumab BGB-A425 + Tislelizumab BGB-A425 + LBL-007 + Tislelizumab Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma Recruiting USA | AUS 4
NCT04802876 Phase II Tislelizumab Spartalizumab Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients With PD1-high mRNA Expressing Tumors (ACROPOLI) Recruiting ESP 0
NCT04952597 Phase II Tislelizumab BGBA1217 + Tislelizumab Study of Ociperlimab Plus Tislelizumab Plus Chemoradiotherapy in Participants With Untreated Limited-Stage Small Cell Lung Cancer Completed USA 2
NCT03745222 Phase III Tislelizumab Cisplatin + Etoposide + Tislelizumab Carboplatin + Paclitaxel + Tislelizumab Cisplatin + Etoposide Carboplatin + Paclitaxel A Study of Tislelizumab (BGB-A317) Plus Chemoradiotherapy Followed by Tislelizumab Monotherapy in Newly Diagnosed, Stage III Subjects With Locally Advanced, Unresectable Non-small Cell Lung Cancer (RATIONALE001) Terminated USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL 15
NCT05366829 Phase II Tislelizumab Tislelizumab Consolidation After Liver-Directed Therapy for Hepatocellular Carcinoma Recruiting USA 0
NCT03783442 Phase III Cisplatin Paclitaxel Tislelizumab Oxaliplatin Fluorouracil Capecitabine A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU | BEL | AUS 8
NCT04813107 Phase Ib/II APL-1202 + Tislelizumab Tislelizumab A Study to Evaluate the Safety and Efficacy of Oral APL-1202 in Combination With Tislelizumab Compared to Tislelizumab Alone as Neoadjuvant Therapy in Patients With Muscle Invasive Bladder Cancer (ANTICIPATE) Recruiting USA 1


Additional content available in CKB BOOST